Association of polyunsaturated fatty acids treatment with coronary mortality. A meta-analysis
https://doi.org/10.18087/cardio.n680
Abstract
Aim. A meta-analysis was undertaken to sum up data on long-chain polyunsaturated fatty acids treatment and coronary deaths. Methods. Only studies with no less than 500 participants and length of follow-up no less than one year were included. Total number of studies was 13 with 127455 participants. Results. Fixed factor (Peto) model demonstrated significant decrease in cardiac deaths in polyunsaturated fatty acids -treated group. (OR=0,89, 95%CI: 0,83-0,95, р=0,001). Random factor model confidence interval also does not included one (OR=0,88, 95%CI: 0,80-0,97, p=0.008). Subgroup analysis of studies that used therapy with 460 mg eicosapentaenoic acid and 380 docosahexaenoic acid per day demonstrated significant reduction in cardiac deaths (OR=0,84, 95%CI: 0,77-0,92) in both fixed factor and random factor models. Conclusion. Correspondingly supplementation with polyunsaturated fatty acids associated with lower coronary mortality.
Supporting agencies: no
About the Authors
S. L. Plavinskii
“I. I. Mechnikov North-West State Medical University” Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Kirochnaya 41, St.-Petersburg 191015
SPIN-code: 5660-4661
A. N. Barinova
“I. I. Mechnikov North-West State Medical University” Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Kirochnaya 41, St.-Petersburg 191015
SPIN code: 2010-4354
K. D. Danishevski
National Research University Higher School of Economics
Russian Federation
Russian Federation
Myasnitskaya str., 20, Moscow 101000
SPIN code: 3038-7167
References
1. ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G et al. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. The New England Journal of Medicine. 2018;379(16):1540–50. DOI: 10.1056/NEJMoa1804989
2. Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L et al. Associations of Omega-3 Fatty Acid Supplement Use with Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals. JAMA Cardiology. 2018;3(3):225–34. DOI: 10.1001/jamacardio.2017.5205
3. Maki KC, Palacios OM, Bell M, Toth PP. Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps. Journal of Clinical Lipidology. 2017;11(5):1152-1160.e2. DOI: 10.1016/j.jacl.2017.07.010
4. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events: A Systematic Review and Metaanalysis. JAMA. 2012;308(10):1024–33. DOI: 10.1001/2012.jama.11374
5. Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2018;7:CD003177. DOI: 10.1002/14651858.CD003177.pub3
6. Bowen KJ, Harris WS, Kris-Etherton PM. Omega-3 Fatty Acids and Cardiovascular Disease: Are There Benefits? Current Treatment Options in Cardiovascular Medicine. 2016;18(11):69. DOI: 10.1007/s11936-016-0487-1
7. Maki K, Dicklin M. Omega-3 Fatty Acid Supplementation and Cardiovascular Disease Risk: Glass Half Full or Time to Nail the Coffin Shut? Nutrients. 2018;10(7):E864. DOI: 10.3390/nu10070864
8. Plavinskii S.L., Barinova A.N. Use of Highly Concentrated Polyunsaturated Fatty Acids for Prevention of Complications After Myocardial Infarction. Cost-Utility Analysis. Kardiologiia. 2018;58(2):77–82. DOI: 10.18087/cardio.2018.2.10089
9. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet (London, England). 1999;354(9177):447–55. PMID: 10465168
10. Manson JE, Cook NR, Lee I-M, Christen W, Bassuk SS, Mora S et al. Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. New England Journal of Medicine. 2019;380(1):23–32. DOI: 10.1056/NEJMoa1811403
11. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. The New England Journal of Medicine. 2019;380(1):11–22. DOI: 10.1056/NEJMoa1812792
12. Schwarzer G. Meta: An R package for meta-analysis. R News. 2007;7(3):40–5. [Av. at: https://cran.rstudio.org/doc/Rnews/Rnews_2007-3.pdf#page=40]
13. Einvik G, Ole Klemsdal T, Sandvik L, Hjerkinn EM. A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk. European Journal of Cardiovascular Prevention & Rehabilitation. 2010;17(5):588–92. DOI: 10.1097/HJR.0b013e328339cc70
14. Bonds DE, Harrington M, Worrall BB, Bertoni AG, Eaton CB, Hsia J et al. Effect of Long-Chain ω-3 Fatty Acids and Lutein + Zeaxanthin Supplements on Cardiovascular Outcomes: Results of the AgeRelated Eye Disease Study 2 (AREDS2) Randomized Clinical Trial. JAMA Internal Medicine. 2014;174(5):763–71. DOI: 10.1001/jamainternmed.2014.328
15. Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c6273. DOI: 10.1136/bmj.c6273
16. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients ( JELIS): a randomised open-label, blinded endpoint analysis. The Lancet. 2007;369(9567):1090–8. DOI: 10.1016/S0140-6736(07)60527-3
17. Kromhout D, Giltay EJ, Geleijnse JM. n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction. New England Journal of Medicine. 2010;363(21):2015–26. DOI: 10.1056/NEJMoa1003603
18. Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H et al. OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction. Circulation. 2010;122(21):2152–9. DOI: 10.1161/CIRCULATIONAHA.110.948562
19. The Risk and Prevention Study Collaborative Group. n–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors. New England Journal of Medicine. 2013;368(19):1800–8. DOI: 10.1056/NEJMoa1205409
20. GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;372(9645):1223–30. DOI: 10.1016/S0140-6736(08)61239-8
21. The ORIGIN Trial Investigators. n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. New England Journal of Medicine. 2012;367(4):309–18. DOI: 10.1056/NEJMoa1203859
Review
For citations:
Plavinskii S.L., Barinova A.N., Danishevski K.D. Association of polyunsaturated fatty acids treatment with coronary mortality. A meta-analysis. Kardiologiia. 2019;59(11S):63-68. (In Russ.) https://doi.org/10.18087/cardio.n680
Views:
882
Email this article 
Post a Comment 
